Accessibility Menu
Genprex Stock Quote

Genprex (NASDAQ: GNPX)

$11.50
(-17.9%)
-2.50
Price as of October 21, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$11.5
Daily Change
(-17.9%) $2.50
Day's Range
$10.11 - $12.97
Previous Close
$11.5
Open
$12.97
Beta
1.31
Volume
259,197
Average Volume
25,927,972
Market Cap
12M
Market Cap / Employee
$0.28M
52wk Range
$0.14 - $157.5
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$2.09
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Genprex Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
GNPX-84.77%-99.83%-72.03%-93%
S&P+15.06%+95.03%+14.29%+155%

Genprex Company Info

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit$0.00M100.0%
Market Cap$330.55M67.1%
Market Cap / Employee$22.04M0.0%
Employees150.0%
Net Income-$4.67M28.0%
EBITDA-$4.68M28.1%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$1.35M-45.2%
Accounts Receivable$0.00M0.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.00M0.0%
Short Term Debt$0.00M0.0%

Ratios

Q2 2025YOY Change
Return On Assets-331.39%-99.2%
Return On Invested Capital-386.77%-190.1%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$3.86M33.3%
Operating Free Cash Flow-$3.86M33.3%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book10.64140.3882.2271.16243.89%
Price to Tangible Book Value10.64140.3882.2271.16212.84%
Enterprise Value to EBITDA0.05-1.76-0.07-1.06325.54%
Return on Equity-325.1%-467.2%-302.7%-602.6%88.99%
Total Debt$0.00M$0.00M$0.00M$0.00M-

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.